Hetong decoction relieves loperamide-induced constipation in rats by regulating expression of aquaporins
CONCLUSIONS: HTT relieves constipation in rats through regulating AQP3 and AQP8 expression.PMID:37946478 | PMC:PMC10623261 | DOI:10.19852/j.cnki.jtcm.2023.06.008 (Source: Journal of Traditional Chinese Medicine)
Source: Journal of Traditional Chinese Medicine - November 10, 2023 Category: Complementary Medicine Authors: Huang Xi Xia Youguang Han Kai Q I Weiwei Linghu Qing Zhang Qing Xue Jingbo Source Type: research
Hetong decoction relieves loperamide-induced constipation in rats by regulating expression of aquaporins
CONCLUSIONS: HTT relieves constipation in rats through regulating AQP3 and AQP8 expression.PMID:37946478 | PMC:PMC10623261 | DOI:10.19852/j.cnki.jtcm.2023.06.008 (Source: Journal of Traditional Chinese Medicine)
Source: Journal of Traditional Chinese Medicine - November 10, 2023 Category: Complementary Medicine Authors: Huang Xi Xia Youguang Han Kai Q I Weiwei Linghu Qing Zhang Qing Xue Jingbo Source Type: research
Hetong decoction relieves loperamide-induced constipation in rats by regulating expression of aquaporins
CONCLUSIONS: HTT relieves constipation in rats through regulating AQP3 and AQP8 expression.PMID:37946478 | PMC:PMC10623261 | DOI:10.19852/j.cnki.jtcm.2023.06.008 (Source: Journal of Traditional Chinese Medicine)
Source: Journal of Traditional Chinese Medicine - November 10, 2023 Category: Complementary Medicine Authors: Huang Xi Xia Youguang Han Kai Q I Weiwei Linghu Qing Zhang Qing Xue Jingbo Source Type: research
Hetong decoction relieves loperamide-induced constipation in rats by regulating expression of aquaporins
CONCLUSIONS: HTT relieves constipation in rats through regulating AQP3 and AQP8 expression.PMID:37946478 | PMC:PMC10623261 | DOI:10.19852/j.cnki.jtcm.2023.06.008 (Source: Journal of Traditional Chinese Medicine)
Source: Journal of Traditional Chinese Medicine - November 10, 2023 Category: Complementary Medicine Authors: Huang Xi Xia Youguang Han Kai Q I Weiwei Linghu Qing Zhang Qing Xue Jingbo Source Type: research
Loperamide induces protective autophagy and apoptosis through the ROS/JNK signaling pathway in bladder cancer
Biochem Pharmacol. 2023 Oct 18:115870. doi: 10.1016/j.bcp.2023.115870. Online ahead of print.ABSTRACTBladder cancer is one of the most common carcinomas in the human urinary system worldwide. Loperamide, known as an antidiarrheal drug, exerts anti-tumor activities against various cancers. However, the effect of loperamide on bladder cancer cells remains unclear. Our study aimed to investigate the effect of loperamide on bladder cancer and explore the underlying mechanisms. We found that loperamide suppressed the proliferation of 5637 and T24 cells in a dose-dependent manner. Loperamide treatment showed both pro-apoptotic a...
Source: Biochemical Pharmacology - October 20, 2023 Category: Drugs & Pharmacology Authors: Jianjian Wu Qiang Guo Juntao Li Hao Yuan Chutian Xiao Jianguang Qiu Qiong Wu Dejuan Wang Source Type: research
Loperamide induces protective autophagy and apoptosis through the ROS/JNK signaling pathway in bladder cancer
Biochem Pharmacol. 2023 Oct 18:115870. doi: 10.1016/j.bcp.2023.115870. Online ahead of print.ABSTRACTBladder cancer is one of the most common carcinomas in the human urinary system worldwide. Loperamide, known as an antidiarrheal drug, exerts anti-tumor activities against various cancers. However, the effect of loperamide on bladder cancer cells remains unclear. Our study aimed to investigate the effect of loperamide on bladder cancer and explore the underlying mechanisms. We found that loperamide suppressed the proliferation of 5637 and T24 cells in a dose-dependent manner. Loperamide treatment showed both pro-apoptotic a...
Source: Biochemical Pharmacology - October 20, 2023 Category: Drugs & Pharmacology Authors: Jianjian Wu Qiang Guo Juntao Li Hao Yuan Chutian Xiao Jianguang Qiu Qiong Wu Dejuan Wang Source Type: research
Cancers, Vol. 15, Pages 5011: Clinical Management of Low Anterior Resection Syndrome: Review of the Current Diagnosis and Treatment
Conclusions: In clinical trials of LARS treatment between 2020 and 2022, the eligibility criteria and evaluation system have been variable. Therefore, it is urgent to create a standard for the diagnosis, assessment, and treatment of LARS. Failure to set placebos and differentiate subgroups are limitations of many current LARS studies. Randomized controlled trials comparing diverse therapies and long-term outcomes are absent, as well. Moreover, a new scale needs to be developed to incorporate the patient’s perspective and facilitate outpatient follow-up. Though the establishment of a stepwise classification mo...
Source: Cancers - October 16, 2023 Category: Cancer & Oncology Authors: Ruijia Zhang Wenqin Luo Yulin Qiu Fan Chen Dakui Luo Yufei Yang Weijing He Qingguo Li Xinxiang Li Tags: Review Source Type: research
Loperamide Misuse Mimicking Symptoms of Severe Malnutrition
Loperamide, an oral over-the-counter μ-opioid receptor agonist used to treat diarrhea, acts primarily in the gut and, when used as recommended, has little to no systemic effect. At high doses, it may cause a “high” like other opioids. Recent literature describes an increasing incidence of loperamide misuse and overdose in the sett ing of the US opioid epidemic. In this case, we describe a 16-year-old with anorexia nervosa who developed dizziness, syncope, and constipation at the time of weight loss. (Source: Journal of Adolescent Health)
Source: Journal of Adolescent Health - October 15, 2023 Category: Child Development Authors: Alana K. Otto, Catherine A. Miller Tags: Clinical observations Source Type: research
Loperamide, a peripheral Mu-Opioid receptor agonist, attenuates chemotherapy-induced neuropathic pain in rats
Int Immunopharmacol. 2023 Oct 4;124(Pt B):110944. doi: 10.1016/j.intimp.2023.110944. Online ahead of print.ABSTRACTOpioids are employed in the management of chemotherapy-induced neuropathic pain (CINP) when other pain management approaches have failed and proven ineffective. However, their use in CINP is generally considered as a second-line or adjunctive therapy owing to their central side effects and development of tolerance with their long-term usage. Targeting peripheral sites may offer several advantages over the conventional CNS-based approaches as peripheral targets modulate pain signals at their source, thereby rel...
Source: International Immunopharmacology - October 6, 2023 Category: Allergy & Immunology Authors: Anagha Gadepalli Obulapathi Ummadisetty None Akhilesh Deepak Chouhan None Anmol Vinod Tiwari Source Type: research
Neratinib for HER2-positive breast cancer with an overlooked option
This article reviewed the pharmacological profiles, efficacy, safety, tolerability, and current clinical trials pertaining to neratinib, with a particular focus on the use of neratinib in patients with metastatic breast cancer (MBC) involving the CNS. We further discussed the use of neratinib for HER2-negative and HER2-mutant breast cancers, and mechanisms of resistance to neratinib. The current evidence suggests that neratinib has promising efficacy in patients with BC which is at least non-inferior compared to previous therapeutic regimens. The most common AE was diarrhea, and the incidence, severity and duration of nera...
Source: Cancer Control - October 6, 2023 Category: Cancer & Oncology Authors: Liting Guo Weiwei Shao Chenfei Zhou Hui Yang Liu Yang Qu Cai Junqing Wang Yan Shi Lei Huang Jun Zhang Source Type: research
Neratinib for HER2-positive breast cancer with an overlooked option
This article reviewed the pharmacological profiles, efficacy, safety, tolerability, and current clinical trials pertaining to neratinib, with a particular focus on the use of neratinib in patients with metastatic breast cancer (MBC) involving the CNS. We further discussed the use of neratinib for HER2-negative and HER2-mutant breast cancers, and mechanisms of resistance to neratinib. The current evidence suggests that neratinib has promising efficacy in patients with BC which is at least non-inferior compared to previous therapeutic regimens. The most common AE was diarrhea, and the incidence, severity and duration of nera...
Source: Molecular Medicine - October 6, 2023 Category: Molecular Biology Authors: Liting Guo Weiwei Shao Chenfei Zhou Hui Yang Liu Yang Qu Cai Junqing Wang Yan Shi Lei Huang Jun Zhang Source Type: research
Loperamide, a peripheral Mu-Opioid receptor agonist, attenuates chemotherapy-induced neuropathic pain in rats
Int Immunopharmacol. 2023 Oct 4;124(Pt B):110944. doi: 10.1016/j.intimp.2023.110944. Online ahead of print.ABSTRACTOpioids are employed in the management of chemotherapy-induced neuropathic pain (CINP) when other pain management approaches have failed and proven ineffective. However, their use in CINP is generally considered as a second-line or adjunctive therapy owing to their central side effects and development of tolerance with their long-term usage. Targeting peripheral sites may offer several advantages over the conventional CNS-based approaches as peripheral targets modulate pain signals at their source, thereby rel...
Source: International Immunopharmacology - October 6, 2023 Category: Allergy & Immunology Authors: Anagha Gadepalli Obulapathi Ummadisetty None Akhilesh Deepak Chouhan None Anmol Vinod Tiwari Source Type: research
Neratinib for HER2-positive breast cancer with an overlooked option
This article reviewed the pharmacological profiles, efficacy, safety, tolerability, and current clinical trials pertaining to neratinib, with a particular focus on the use of neratinib in patients with metastatic breast cancer (MBC) involving the CNS. We further discussed the use of neratinib for HER2-negative and HER2-mutant breast cancers, and mechanisms of resistance to neratinib. The current evidence suggests that neratinib has promising efficacy in patients with BC which is at least non-inferior compared to previous therapeutic regimens. The most common AE was diarrhea, and the incidence, severity and duration of nera...
Source: Cancer Control - October 6, 2023 Category: Cancer & Oncology Authors: Liting Guo Weiwei Shao Chenfei Zhou Hui Yang Liu Yang Qu Cai Junqing Wang Yan Shi Lei Huang Jun Zhang Source Type: research
Proteasome inhibition protects blood –brain barrier P-glycoprotein and lowers Aβ brain levels in an Alzheimer’s disease model
ConclusionsOur data indicate that BTZ protects P-gp from proteasomal degradation in hAPP mice, which helps to reduce A β brain levels. Our data suggest that the proteasome system could be exploited for a novel therapeutic strategy in AD, particularly since increasing Aβ transport across the blood–brain barrier may prove an effective treatment for patients. (Source: Fluids and Barriers of the CNS)
Source: Fluids and Barriers of the CNS - October 6, 2023 Category: Neuroscience Source Type: research
Altered intestinal barrier contributes to cognitive impairment in old mice with constipation after sevoflurane anesthesia
CONCLUSION: Aged STC mice were more vulnerable to sevoflurane anesthesia and consequently developed POCD-like behavioral changes. Our data suggest that gastrointestinal disorders including constipation may contribute to the development of POCD.PMID:37771755 | PMC:PMC10523324 | DOI:10.3389/fnut.2023.1117028 (Source: Cancer Control)
Source: Cancer Control - September 29, 2023 Category: Cancer & Oncology Authors: Tianyun Zhao Junming Lu Jingwen Qin Yanxin Chen Ziwen Shi Wei Wei Peng Xiong Daqing Ma Xingrong Song Source Type: research
